Journal Information
Vol. 111. Issue 5.
Pages 426-429 (June 2020)
Vol. 111. Issue 5.
Pages 426-429 (June 2020)
Case and Research Letters
DOI: 10.1016/j.adengl.2020.04.010
Open Access
Chilblain and Acral Purpuric Lesions in Spain during Covid Confinement: Retrospective Analysis of 12 Cases
Lesiones pernióticas y acrales en España durante el confinamiento por COVID: análisis retrospectivo de 12 casos
Visits
...
J. Romanía,
Corresponding author
jromani@tauli.cat

Corresponding author.
, E. Baselgab, O. Mitjàc, N. Riera-Martíc, P. Garbayoa, A. Vicenteb, M. Casalsa, V. Fumadód, C. Fortunyd, S. Calzadoe
a Departamento de Dermatología, Consorci Sanitari Parc Taulí, Sabadell, Barcelona, Spain
b Departamento de Dermatología, Hospital Sant Joan de Deu, Barcelona, Spain
c Enfermedades Infecciosas y Salud Global, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
d Departamento de Enfermedades Infecciosas, Hospital Sant Joan de Deu, Barcelona, Spain
e Departamento de Enfermedades Infecciosas, Consorci Sanitari Parc Taulí, Sabadell, Barcelona, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (1)
Table 1. Patients’ characteristics.
Full Text
Dear Editor:

Since the emergence of COVID-19 infection in Spain, in the beginning of February 2020, the most populated regions, such as Madrid and Catalonia, have concentrated the highest case incidence. Suspect of COVID-19 is based on clinical signs comprising fever, cough, fatigue, ageusia, anosmia, myalgia and dyspnea. Laboratory alterations include lymphopenia, increased LDH, D Dimer, Ferritin and CRP. The diagnosis is based on virus detection in oropharyngeal swabs. Some rapid tests are available for seroconversion detection, for determination of specific IgM and IgG, but its use is still limited due to low availability, and uncompleted validation. Restricted measures have been performed in the Spanish population. Alarm state and general confinement in Spain started in March 14th and has not yet been finished.

A number of dermatoses associated with covid-19 infection have already been described,1 including erythematous or purpuric rash in the trunk, urticarial and chickenpox-like lesions. Acro-ischemic lesions have been reported in intensive care unit-admitted patients,2 due to disseminated intravascular coagulation (DIC) and clinically behaving as a dry gangrene. A case of acute acro-ischemic lesions in a child has recently been reported in Italy.3

During the first weeks of April, national and regional social media have reported a vast number of chilblain-like purpuric acral lesions in hands and feet, predominating in children, and up to date, accurate descriptions in the existing medical literature have been sparse.3 In Spain, reports of these lesions have been widespread in the territory, but they have been more frequently reported on the most populated areas, the Metropolitan Conurbations of Madrid and Barcelona.

We have retrospectively reviewed 12 cases of acral purpuric lesions that have been studied thoroughly in two hospitals in the Barcelona area (Consorci Sanitari Parc Taulí and Hospital Sant Joan de Deu). Their clinical characteristics are shown in Table 1. None of them had COVID-related clinical manifestations. Most patients were children and young adults. Clinical picture comprised two types of lesions: 1. Acral erythematous purpuric lesions in fingers and toes, with accompanying edema, similar to common chilblains or pernio (Figure 1), sometimes evolving into blisters, and crusts. Hands and feet were not cold, and the symptoms usually ranged from itch to burning or painful sensations; 2. Papular or macular purpuric round-shaped lesions, 5 to 8mm of diameter, in palmar or plantar surfaces, or over the heels (Figure 2), clinically resembling vasculitis or erythema multiforme, usually asymptomatic or itchy. The two types of lesions were present alone or in combination.

Table 1.

Patients’ characteristics.

Patient number  Hospital  Age  Sex  Clinical presentation  Treatment and Evolution  COVID-19 infection symptoms  PCR  IgM/IgG rapid test  Biopsy  Laboratory  Chest x-ray 
CSPT  43  Male  Chilblain-like lesions on hands and feet  Topical corticosteroid+antibiotic. Healing in 2 weeks  No  —  —  Yes  Ferritin 423,9ng/ml  Normal 
CSPT  46  Male  Purpuric papules on hands  Topical corticosteroid. Healing in 1 week  No  —  —  Yes  Normal  Normal 
CSPT  12  Male  Chilblain-like lesions in feet, purpuric papules on heels  Topical corticosteroid+antibiotic. Healing in 3 weeks  No  —  —  No  Normal  Normal 
CSPT  14  Male  Purpuric papules on heels  Topical corticosteroid. Healing in 2 weeks  No  —  —  No  Normal  Normal 
CSPT  Female  Chilblain-like on hands and feet. Palmar involvement  Topical antibiotic. Healing in 1 week  No  —  —  No  Normal  Normal 
CSPT  15  Female  Itchy chilblain-like lesions on feet  3 weeks evolution, spontaneous improvement  No  —  N/A  No  N/A  N/A 
CSPT  12  Male  Itchy chilblain-like  Improvement with topical  No  —  N/A  No  Normal  N/A 
CSPT  14  Female  Itchy and burning chilblain-like lesions on feet  Improvement with topical corticosteroid in 3 weeks  No  —  N/A  No  Normal  N/A 
HSJD  14  Female  Erythromelalgia symptoms, chilblain lesions on feet, edema, and blistering  Very intense symptoms, not relieved with aspirin, gabapentin needed to control pain  No  —  N/A  No  Normal  N/A 
10  HSJD  17  Male  Perniosis-like and blisters on hands and feet  N/A  No  —  N/A  No  N/A  N/A 
11  HSJD  11  Female  Chilblain-like lesions on hands and feet  Spontaneous improvement in 2 weeks  No  —  N/A  No  Normal  N/A 
12  HSJD  17  Female  Purpuric papules and vesicles on fingers  Improvement in 3 weeks with topical corticosteroid  No  —  N/A  No  Normal  N/A 

CSPT: Consorci Sanitari Parc Taulí; HSJD: Hospital Sant Joan de Deu; N/A: not available.

Figure 1.

Chilblain-like lesions and edema in hands and feet.

(0.15MB).
Figure 2.

Discrete papular purpuric round-shaped lesions predominantly on plantar surfaces or heels.

(0.12MB).

The results of COVID-19 screening yielded negative results in all cases, including specific PCR and a rapid test for IgM/IgG antibodies (VivaDiag, VivaCheck Biotech, Hangzhou, China), performed only in 5 patients due to current low availability. Laboratory tests (including blood cell count, ferritin, CRP, D Dimer, Ferritin and LDH) and chest X-ray, when available, showed normal or negative results. In two patients, a histopathological study of a punch biopsy of the lesions yielded nonspecific findings, with dermal edema, sparse keratinocyte necrosis, and a deep mixed infiltrate with mostly perivascular or perieccrine reinforcement.

All cases showed a good evolution, achieving a complete healing after two to three weeks of topical corticosteroid or combination of topical corticosteroid plus topical antibiotic. In only one patient, pain control needed the administration of oral gabapentin. None of the patients have develop any COVID-related clinical manifestation since the diagnosis of skin lesions.

As a conclusion, this stunning clinical picture is atypical because it has appeared during warm weather, not associated with common chilblains, and although it has a temporal relationship with COVID pandemic, in none of the patients an evidence of current or past COVID-19 infection could be demonstrated. Epidemiological association is clear with COVID-19 pandemic, but our results show that such cutaneous lesions are not a manifestation of active coronavirus infection, as determined by currently available tests. One explanation could be an early contact with COVID-19 during the month of February or early March, without clinical symptoms, which would have made the virus undetectable with PCR technique. A second explanation could be low sensibility of the rapid IgG/IgM tests, or a fast disappearance of circulating antibodies, with low levels that do not match the technique detection threshold. A third one would comprise different etiopathogenic factors related to confinement, which have not been identified up to date. A more detailed study of more skin biopsies, self-immunity profiling in serum, and more refined quantitative PCR detection are in course, in order to elucidate the cause of these dermatological lesions.

Conflict of interest

The authors declare that they have no conflict of interest.

References
[1]
S. Recalcati.
Cutaneous manifestations in COVID-19: a first perspective.
J Eur Acad Dermatol Venereol, (2020),
[2]
Y. Zhang, W. Cao, M. Xiao, Y.J. Li, Y. Yang, J. Zhao, et al.
Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia.
Zhonghua Xue Ye Xue Za Zhi, 41 (2020), pp. E006
[3]
Mazzotta F, Troccoli T. A new vasculitis at the time of COVID-19. Eur J Pediatr Dermatol (Monday's case). Available from: http://ejpd.com [accessed 13.04.20]

Please cite this article as: Romaní J, Baselga E, Mitjà O, Riera-Martí N, Garbayo P, Vicente A, et al. Lesiones pernióticas y acrales en España durante el confinamiento por COVID: análisis retrospectivo de 12 casos. Actas Dermosifiliogr. 2020;111:426–429.

Copyright © 2020. AEDV
Idiomas
Actas Dermo-Sifiliográficas (English Edition)

Subscribe to our newsletter

Article options
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
  • Additional material
Tools
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1273])
Supplemental materials
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.